The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The only people that are selling should be those that need the cash or like to trade regularly. I think some PI's are now realising that this isn't an oily or disco company that's going to go up 50-100% on an RNS. It's a state of the art small cap tech Co that has unique and groundbreaking tech in a massive market sector. I'm holding here for the inevitable buy out that will come along probably from a huge CRO in the next couple of years. Market cap then should be 100M min ...so a 5 bag from here min imo. I don't need to waste time trading or sp watching as GR is the man on a mission and he wants this to be his last and most successful hurrah! Buy as many as you can afford, sit back and be happy to watch this unfold with a great ethical bonus thrown in...Hopefully it stays down here for another 8 weeks as I've another 40K to throw in, but I expect more news flow between now and then so will probably pay a bit more...
the last 2 RNS have been really strong - c900% growth and additional large contracts with leading players.
This shows that the technology they have is unique and there is a strong demand for it. Sub 2p is just madness.
With extra lab space and Beta testing now being completed this really opens up more opportunities for SKIN. In Gerry we trust!!!
Really happy with today's news. LabskinAI coming out of the testing phase should be a real kicker for the company. Without it they would have done really well but with it.. this is transformation. They are no longer selling just a physical product but a virtual service to accompany it. The markups here will be gold dust.
Justdavie,I’m the same 2p is unbelievable for what’s available here,unless I’m being royally sucked in here,why anyone would sell just now is crazy....long term for me GLA
TIDM: SKIN
RNS Number : 0488G
Integumen PLC
19 July 2019
AIM share code: SKIN
19 July 2019
Integumen PLC
("Integumen" or "Company")
LabskinAI wins new agreements with two Top-10 global cosmetic companies
Integumen today announces that LabskinAI has signed new agreements with two of the Top-10 global cosmetic companies for initial testing on ingredients and products in their portfolio.
These contracts demonstrate an increase in revenue per client as previous clients upgrade from Labskin products purchases to a full virtual service offering and are worth in aggregate in excess of GBP100,000 with the potential for continued testing thereafter. Signed in the first month of H2 2019, these agreements are in addition to the contracts in H1 announced in RNS of 28th May 2019.
Today we also announce that LabskinAI has now completed Beta testing and has fully transitioned from a product sale only company to a virtual and physical test platform for healthcare, personal care, skincare, wound care and pharmaceutical drug discovery eco-system.
LabskinAI contracts, which are EU Regulatory driven, illustrate that LabskinAI virtual services and delivery of physical Labskin services using sophisticated technology integration have the potential to elevate skincare product development. These latest agreements endorse Labskin as an ideal partner to global companies for microbiome testing for consumer skin care products and ingredients.
Gerard Brandon (Chief Executive Officer) commented:
"Integumen is playing a major role in the creation of an innovative AI eco-system that will contribute to the growth of our clients' product range as they develop new skin care products using the LabskinAI virtual platform.
"Right now, LabskinAI serves as a portal for small, medium and large corporations to meet the strict EU regulatory requirements for existing products that are already on the shelf. The repeat custom of two global cosmetic companies is testament to the value of the LabskinAI platform for the entire skin care industry."
This website is not showing it in error, I use sharescope pro for my news feed, prices, and charts but normally this website would show it.
I will copy paste it for you.
yes not showing here
This really is great news for the company.
* New Contracts
* Potential recurring revenue
* Relationships with clients with huge portfolios that will require SKINs services and products.
* LabskinAI has now completed Beta testing and has fully transitioned from a product sale only company to a virtual and physical test platform
When the doors swing open you walk through them.